Zobrazeno 1 - 10
of 14 451
pro vyhledávání: '"epithelial ovarian-cancer"'
Autor:
Intisar Pity, Ghasaq Kareem, Dildar Musa, Abdulkareem Sulaiman, Shang Salih Amedi, Hayam Rasoul, Yasmine Abdalwahab, Dani Hayder
Publikováno v:
Al-Anbar Medical Journal, Vol 20, Iss 2, Pp 200-206 (2024)
Background: Foremost, the diagnosis of ovarian carcinoma is light microscopic in nature. However high-graded tumors and some equivocal cases may require contemporary tests.Objectives: To examine ovarian carcinoma types in Duhok-Iraq using morphology
Externí odkaz:
https://doaj.org/article/479c36784a1b4fa9abfa73e4eaece7ff
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Predicting chemorefractory disease in advanced epithelial ovarian cancer (EOC) remains challenging. This study aimed to identify clinicopathological factors and hemogram data as predictive markers for chemorefractory EOC and to ex
Externí odkaz:
https://doaj.org/article/6064d6fe927f496ba9389fa29dc46d0d
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-12 (2024)
Abstract Background Near-infrared fluorescence (NIRF) imaging is an excellent choice for image-guided surgery due to its simple operation and non-invasiveness. Developing tumor-specific fluorescent molecular probes is key to fluorescence imaging-guid
Externí odkaz:
https://doaj.org/article/3cafdf3344aa4de18a2379d5052ab62d
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Objective The study aimed to assess the effect of lymph node dissection on survival outcomes in patients presenting with early-stage epithelial ovarian cancer and to delineate patient characteristics that may indicate a greater benefit from
Externí odkaz:
https://doaj.org/article/b63f1de00627441eb3083985ed2462f0
Autor:
Yumei Zhou, Junfen Xu
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-8 (2024)
Abstract Objective Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithelial ovarian cancer. In this re
Externí odkaz:
https://doaj.org/article/bd84da3c752c4034a31799df2dea042b
Autor:
Xuqin Feng, Qian Wang
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Background Keratin-15 (KRT15) involves in the progression and owns prognostic values in several solid cancers, whose clinical role in epithelial ovarian cancer (EOC) is rarely reported. This study aimed to identify the association of KRT15 e
Externí odkaz:
https://doaj.org/article/0374e153d9824169a7e5f5f2b2f8681e
Autor:
Edyta Paradowska, Daria A. Haręża, Katarzyna D. Kania, Dariusz Jarych, Miłosz Wilczyński, Andrzej Malinowski, Monika Kawecka, Mateusz Nowak, Jacek R. Wilczyński
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Human papillomaviruses (HPVs) and herpesviruses are detected in patients with epithelial ovarian cancer (EOC). We sought to analyze the prevalence of HPV’s 16 and 18, cytomegalovirus (CMV), and Epstein-Barr virus (EBV) DNA in peripheral bl
Externí odkaz:
https://doaj.org/article/bf6690b3ca454ba1b3eaf2a69538f88f
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background The main challenge in treating ovarian cancer is chemotherapy resistance. Previous studies have shown that PAK2 is highly expressed in various cancers. This research investigates whether increased PAK2 expression contributes to ch
Externí odkaz:
https://doaj.org/article/924ed74a13554fec92680f5347d07890
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies worldwide. The aim of this retrospective study was to create a predictive scoring model based on simple immunological and inflammatory parameters
Externí odkaz:
https://doaj.org/article/c60b0b4ec3cd42ac89d7c1db1e538102
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-8 (2024)
Abstract Objective The current research aims to evaluate the efficacy and safety of anlotinib, an orally administered small-molecular tyrosine kinase inhibitor (TKI), in the treatment of recurrent epithelial ovarian cancer (EOC). Methods Patients wit
Externí odkaz:
https://doaj.org/article/9f508d98de1542779fbccaa960261f59